- Tracer Biotechnologies partners with QIAGEN (QGEN, Financial) to develop and commercialize MRD assays for solid tumors.
- The collaboration aims to utilize QIAGEN's QIAcuity digital PCR platform for cost-effective and decentralized cancer monitoring solutions.
- Tracer's MRD solutions offer personalized treatment options and enhance clinical workflows.
Tracer Biotechnologies has announced a strategic collaboration with QIAGEN (QGEN) to co-develop and market minimal residual disease (MRD) assays specifically for solid tumors. These assays will be hosted on QIAGEN's advanced QIAcuity digital PCR platform. The partnership seeks to deliver innovative, sensitive, and cost-efficient MRD testing solutions designed to help oncologists monitor cancer recurrence using minimally invasive blood samples.
Mark Kaganovich, CEO of Tracer Biotechnologies, highlighted the advantages of the partnership, stating, "Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform in QIAcuity." This collaboration is expected to provide high-quality companion diagnostics that easily integrate into clinical workflows and offer new personalized treatment decisions for oncologists and patients.
The agreement introduces two key MRD solutions from Tracer: Tracer dPCR, a tumor-informed, multiplexed digital PCR assay; and Tracer WGS, an AI-powered whole-genome ctDNA platform. These technologies facilitate ultra-sensitive, tumor-agnostic detection and monitoring without prior tissue samples.
Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics at QIAGEN, expressed enthusiasm for the collaboration, emphasizing how it reinforces QIAGEN's significant role in oncology. The partnership aims at fortifying scalable and cost-effective solutions based on the QIAcuity digital PCR system, providing pharmaceutical partners with essential MRD insights for guiding personalized cancer treatment outcomes.
Tracer Biotechnologies is driven by their mission to empower institutions and clinicians globally with sophisticated tools like digital PCR machines and next-generation sequencers, promoting decentralized testing, swift treatment decisions, and personalized cancer care.
For further information, visit the [Tracer Biotechnologies website](http://www.tracerbio.com) and [QIAGEN's website](http://www.qiagen.com).
